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Abstract  
 
Background:  Thyroid function tests (TFT) are among the most requested tests internationally. 
Testing practice is however inconsistent and potentially sub-optimal and overly costly. The natural 
history of thyroid function remains poorly understood.  
 
Aim: To establish the stability of thyroid function over time, and identify predictors of development 
of overt thyroid dysfunction 
Design: Longitudinal follow-up 
 
Setting: 19 general practices, UK 
 
Method: 2936 Birmingham Elderly Thyroid Study (BETS I) with a baseline TFT result indicating 
euthyroid or subclinical state were re-tested after approximately 5 years. Change in TSH, FT4 and 
thyroid status between baseline, and follow-up was determined.  Predictors of progression to 
overt dysfunction were modelled. 
 
Results: Participants contributed 12,919-person years, 17 cases of overt thyroid dysfunction 
were identified, 13 having been classified at baseline as euthyroid and four as having subclinical 
thyroid dysfunction. Individuals with subclinical results at baseline were 10 and 16-fold more likely 
to develop overt hypo and hyperthyroidism respectively compared with euthyroid individuals. TSH 
and FT4 demonstrated significant stability over time with 61% of participants having a repeat TSH 
concentration within 0.5 mIU/L of their original result. Predictors of overt hypothyroidism included 
new treatment with amiodarone (OR 92.1), a new diagnosis of atrial fibrillation (OR 7.4), or renal 
disease (OR 4.8).   
 
Conclusion: High stability of thyroid function demonstrated over the 5-year interval period should 
discourage repeat testing, especially where a euthyroid result is in the recent clinical record. 
Reduced repeat TFTs in older individuals is possible without conferring risk and could result in 
significant cost savings. 
 
Key terms: Thyroid function test, Subclinical thyroid dysfunction, symptoms, aging, primary 
health care, general practice   
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How this fits in 
 
• Thyroid tests are commonly requested in the routine care of older adults. 
• Subclinical thyroid dysfunction is a relatively common biochemical finding among elderly 
patients.  
• Current practice for the management of a single test indicating mildly abnormal thyroid 
dysfunction in the elderly population is variable and potentially sub-optimal and overly 
costly.   
• This large, population-based survey demonstrates significant stability in thyroid function 
over a period of up to 5 years in the elderly population, with 96% of individuals who were 
euthyroid at baseline remaining so and less than 0.5% developing an overt hyper or 
hypothyroid status.   
• Based upon this evidence, routine repeat thyroid function testing among elderly individuals 
who have a recent (within 5 years) euthyroid result in their clinical record is not advised, 
unless clinically indicated.  
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Introduction  
Disorders of the thyroid include both overt and subclinical hypothyroidism and hyperthyroidism. 
Subclinical thyroid dysfunction is common among the elderly, characterised by serum thyroid 
stimulating hormone (TSH) outside the reference range in association with serum thyroid 
hormone (free thyroxine (FT4) and triiodothyronine (FT3)) concentrations within the reference 
range.1-3  Both subclinical thyroid states are of limited clinical relevance.  In overt thyroid disease 
states, clinicians are generally more concerned about hypothyroidism since onset is often non-
specific and insidious, so the diagnosis is often missed. In contrast, hyperthyroidism will normally 
present with less common symptoms and be diagnosed promptly.   
Within the UK, systematic screening is not recommended, partly because ‘the natural history of 
thyroid function is unclear’.4 Since there is also uncertainty over management of subclinical 
disease, current practice is both variable and potentially sub-optimal or excessively costly.5–7  
Recommendations for how often thyroid function tests (TFTs) should be repeated after a 
previously normal or subclinical test result are lacking. The annual estimated cost of TFTs in the 
UK is £30 million with the majority originating in primary care.5, 8–9 Recent work undertaken by the 
authors suggests that annually in UK general practice, TFTs are requested for around 30% of 
older patients without overt thyroid dysfunction (unpublished data). Available evidence suggests 
that Primary Care Physicians (PCPs) repeatedly request TFTs in this patient group, in response 
to vague symptoms, previously mildly abnormal tests or as part of other routine care monitoring. 8 
Few studies have explored the natural history of thyroid dysfunction or the value of a single TFT 
within a primary care population. One small single-site primary care based study followed 73 
patients with subclinical hypothyroidism for 12 months, reporting that 17.8% developed overt 
disease and 5.5% reverted to a euthyroid state.1 Follow-up of the Whickham cohort identified 
increased odds of development of overt disease if an elevated TSH had previously been 
reported, but the 20-year interval used in this study and all-age cohort make application of 
findings to an elderly population difficult.10  
Secondary care studies are conflicting with one study reporting an incidence of 9.9 overt cases 
per 100 patient years and a study with longer follow up suggesting an annual incidence of 5.6, 
although the female-only population derived from secondary care limits generalisability.11,12 A 
further female only cohort study of 252 individuals referred for elevated TSH reported a similar 
progression with 19% requiring treatment for overt dysfunction or persistent elevated TSH (>10 
mIU/l) over a 5 year interval13. This Brazilian study was conducted in a region of iodine intake 
inadequacy and relevance to the UK may be lacking. Whilst both populations and biochemical 
definitions of thyroid dysfunction differ, the much lower annual incidence reported in secondary 
care populations compared to the primary care study indicates more evidence is needed to 
identify predictors of overt disease outside of the secondary care setting.  
BETS 2 BJGP 06/04/18 
4 
Evidence for the progression of subclinical hyperthyroidism is similarly lacking. Sawin et al14 
reported that none of the 33 subclinically hyperthyroid patients they followed up for 4 years 
developed overt disease and similar findings are reported by Woeber15 with only 1 of 16 patients 
followed developing overt disease.  Whilst these findings demonstrate consistency, numbers are 
small and a recent expert panel review concluded there was insufficient evidence to comment on 
the natural history of subclinical hyperthyroidism.5  
This study aimed to address some of the important gaps in the evidence base, namely to (i) 
determine incidence of subclinical thyroid dysfunction in an elderly primary care population 
previously shown to be euthyroid (ii) establish the proportion of patients with subclinical thyroid 
dysfunction who revert to a euthyroid state, experience persisting subclinical dysfunction or 
develop overt disease (iii) evaluate within-person variation in TSH and FT4 concentrations over a 
5 year interval, and (iv) identify predictors of progression to overt hyper/hypothyroidism. 
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Methods  
Background to the Birmingham Elderly Thyroid Study (BETS I) 
This study comprises follow-up of the BETS I cohort, a screening study of 5881 patients aged 
over 65 from 20 practices representative of the UK, conducted between 2002 and 2004. 16-19 
Thyroid function tests comprised measurement of TSH and FT4. Measurement of FT3 was 
undertaken as dictated by routine laboratory protocol.  
 
Practice recruitment  
19 of the original 20 practices agreed to participate.  
 
Inclusion criteria  
▪ Patients identified in BETS I as having thyroid function results within normal or subclinical 
ranges. A euthryroid status was defined as both TSH and FT4 being within ranges 
indicated in Table 1.  Subclinical hypothyroidism and hyperthyroidism were defined as FT 
4 in range and TSH being above or below reference range respectively. 
 
Exclusion criteria  
BETS I participants  
• for whom classification of thyroid status was not possible, or who had overt thyroid 
dysfunction at baseline 
▪ who were recruited to the active treatment arm of the RCTembedded within BETS 117 
▪ for whom the responsible clinician deemed contact inappropriate 
▪ unable or unwilling to give informed consent 
 
Study procedure 
All eligible patients were sent an invitation letter, patient information sheet, and response return 
slip, after receipt of which screening appointments were organised at their usual surgery. TFTs 
for BETS 2 occurred over a 9-month period, approximately 5 years after the initial screening.  
 
Case note evaluation 
Data on diagnoses and treatment including known confounders such as amiodarone (which 
comprises 37% iodine) were collected from primary care records.  All significant medical 
diagnoses were categorised in accordance with recognised major disease groups as reported in 
BETS I.16 
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For participants having thyroid surgery, radio-iodine therapy or starting anti-thyroid drugs, and 
thyroxine replacement therapy in the interval period, the results of the TFTs immediately prior to 
commencement of treatment were extracted. If one or both measurements had not been 
conducted immediately prior to initiation of treatment, medical records were reviewed to ascertain 
reason for commencement of therapy and enable classification of thyroid status. 
 
Measurement and categorisation of thyroid function  
TFTs were measured by electrochemiluminescent immunoassays (Roche E170, Roche 
Diagnostics, UK).  The TSH assay was calibrated against the second International Reference 
Preparation 80/558 (lower limit of reporting; 0·02 mIU/L, manufacturer’s quoted mean functional 
sensitivity; 0·014 mIU/L). Laboratory reference ranges are reported in Table 1. Changes in the 
assays used to measure TSH, FT4 and FT3 occurred between the two studies.16 In parallel with 
this, a change to the standard reference ranges for TSH, FT4, and FT3 occurred.  To enable 
comparison across the two-time points, a correction factor was applied to the baseline TFT 
results and subsequent reclassification of thyroid status was undertaken before data were 
compared across the time interval. 
Thyroid status was classified as euthyroid, subclinically hypothyroid, overtly hypothyroid, 
subclinically hyperthyroid or overtly hyperthyroid based upon the reference ranges reported in 
Table 1.  
Follow-up contribution in terms of patient years at risk was calculated for all subjects as the time 
interval between initial and follow-up screen. Those receiving thyroid function treatment were 
classified based upon the results of the TFT immediately prior to commencement of treatment 
and their contribution censored at this point.  
 
Primary analysis  
Incidence was calculated as number of cases divided by number of person-years at risk. Risks of 
developing disease were calculated, and risks compared for groups who were categorised as 
euthyroid and subclinical at BETS I. Sensitivity analysis was performed reclassifying all patients 
who commenced therapy during the interval period as having overt thyroid dysfunction (e.g. overt 
hyper or hypothyroidism based upon treatment given) and re-running analyses.  
 
Binary logistic regressions were performed to identify predictors of development of overt 
hyper/hypothyroidism. The forward stepwise LR method was used to identify variables with a 
significance level of 5% for inclusion and 10% for removal. Two additional variables were created, 
one to indicate subclinical thyroid status at BETS I and the other to indicate whether BETS I 
thyroid function status had been reclassified due to the application of the laboratory defined 
correction factors.  In total, 31 variables were available for construction of r models including 
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medical conditions (classed as absent/pre-existing/new (occurring in the interval between 
studies)), amiodarone use, alcohol intake, smoking status, family history of thyroid dysfunction, 
age, and deprivation measure (IMD 2004 score).20 
Analyses were undertaking using SPSS 15.0. 
 
Exploratory analysis 
To explore stability of TSH and FT4 over time, change in both measures between BETS I and 
BETS 2 was calculated for each participant and BETS I values plotted against BETS 2 values to 
explore within-person change.  
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Results 
Eligibility for follow-up 
Overall 103 BETS I participants were ineligible for follow-up (Figure 1). A further 1335 were 
deceased or excluded prior to invitation. Just under 50% of the BETS I cohort (n=2936) fulfilled 
the inclusion criteria and attended for follow-up. Those available to follow-up demonstrated a 
statistically significant difference in deprivation scores and age compared to those not available to 
follow-up. The screened cohort had baseline IMD scores indicative of marginal greater affluence 
(mean IMD 21.65 versus 25.65) and were on average 1.82 years younger.  This difference is 
likely to be attributable to greater mortality in older and less affluent participants, but given the 
large sample and 5 year follow-up period of an older adult cohort these difference are unlikely to 
impact findings. 
 
Population characteristics 
Age ranged from 68·7–96·4 years with a mean of 76·9 years (standard deviation 5·03) and 49% 
were female. Socioeconomic status ranged from 3·16 (most affluent) to 74·4 (least affluent), 
mean IMD score; 21·79 (SD 15·14).   
Overall 92·3% (2709/2936) were classified as euthyroid, 1% (n=29) subclinically hyperthyroid, 
6·2% (n=181) subclinically hypothyroid, 0·3% (n=8) were classified as overtly hyperthyroid and 
0·3% (n=9) overtly hypothyroid.  1·8% (53/2396) had a thyroid diagnosis or treatment in the 
interim period and were classified based upon the TFT immediately prior to treatment 
commencement.  
 
Status change over time 
Overall, 95.5% (95% CI 94.7, 96.3%, 2644/2768) of the individuals classified as euthyroid at 
baseline retained euthyroid status at follow-up.  Six (0·2%, 95%CI 0.1, 0.5%) classified as 
euthyroid at baseline had developed overt hypothyroidism, and seven (0·3%, 95% CI 0.1, 0.5%) 
had developed overt hyperthyroidism. Only 3·5% (95%CI 2.9, 4.3%, 98/2768) had follow-up 
results indicative of a change from euthyroid to subclinical hypothyroidism, and 0·5% (95% CI 
0.3, 0.8%), 13/2768to subclinical hyperthyroidism (Table 2).  
 
Of the 25 individuals classified as subclinically hyperthyroid at baseline, 16 (64%, 95%CI 42.5, 
82.0%) retained this classification, eight (32%, 95%CI 15.0, 53.5%) reverted to euthyroid status, 
and one (4%, 95% CI 0.1, 20.4%) individual developed overt hyperthyroidism. A similar 
proportion, 58% (95%CI 49.5, 66.2%, n=83/143), classified as being subclinically hypothyroid at 
baseline remained so, 40% (95% CI 31.8, 48.4%, n=57) reverted to euthyroid status whilst 2% 
(95%CI 0.4, 6.0%, n=3) developed overt hypothyroidism.  
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Sensitivity analysis  
Since therapy may have disrupted natural history and dysfunction progression, all treated cases 
were re-categorised as having overt thyroid dysfunction.  The total number of cases of overt 
hypothyroidism assumed therefore increases to 51 (26 being euthyroid and 25 subclinical at 
baseline), suggesting that a maximum of 1·7% may have developed overt hypothyroidism 
compared to the 0·3% estimate based upon TFT results alone. The total number of cases of overt 
hyperthyroidism remains the same because in all cases therapy was commenced based upon 
TFT results in the overt range.  
 
Cases of overt dysfunction 
Overall, 2936 participants contributed 12,919 person-years for analysis. The risk of developing 
overt hypothyroidism in the subclinical hypothyroid group was 51·5 per 10,000 person-years at 
risk (95% CI 38.8, 67.1) compared to 4·9 (95% CI 1.6, 10.2) per 10,000 person-years at risk in 
the euthyroid group, making the subclinical group 10 times more likely to develop overt 
hypothyroid dysfunction.  
Sensitivity analyses increases risk for an individual with a subclinical hypothyroid status to 20 
times that for a euthyroid individual 429·5 (95%CI 390.3, 471.9) versus 21·3 (95% CI 13.8, 32.1) 
per 10,000 person-years at risk respectively). It is noted that true risk is likely to be magnified in 
sensitivity analyses due to inclusion of 20 individuals who were euthyroid at baseline but treated 
with thyroxine during the interval period based on a subclinical result.   
 
The risk of an individual with a subclinical hyperthyroid status developing overt hyperthyroidism 
was approximately 16 times greater than that of an individual with a euthyroid status 95·4 (95% 
CI 7.8, 116.1) versus 5·7 (95% CI 2.2, 11.7) per 10,000 person-years at risk respectively).  
 
Predictors of development of overt thyroid dysfunction 
Given the low number of events (overt thyroid disease) it was not possible to produce a robust 
model  to predict development of overt dysfunction.  However given that to achieve sufficient 
events for modelling, over 14 thousand individuals would require follow up (from a 28 thousand 
baseline population, based on our follow-up), we have provided a cautious model based on 
available data to identify factors which appear to increase risk of development of hypothyroidism.  
(Table 3). Individuals with higher TSH or lower FT4 values at baseline are at greatest risk of 
development of overt hypothyroid status.  Later diagnoses of atrial fibrillation or renal disease, or 
commencement of amiodarone also increase likelihood of progression. 
The model constructed to predict development of hyperthyroidism failed to demonstrate any 
predictors, which is not surprising given the very low event rate..  
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Change in TSH and T4  
Change in TSH between BETS I and BETS 2 was calculated and explored using an arbitrary 
definition of a shift of ≥0·5 units being classified as ‘change’. 61% of participants showed no 
change between BETS I and BETS 2 using this definition. Removal of outliers further 
demonstrates equal numbers of individuals experiencing an increase and decrease in TSH 
between time points, and, for the majority, TSH remains relatively stable.  (Figure 2).  
Change in FT4 was calculated based upon a definition of change as ≥1·0 unit, 39·6% (n=1162) of 
participants showed no change using this definition with very few individuals demonstrating large 
shifts in FT4 (Figure 3).  
  
BETS 2 BJGP 06/04/18 
11 
Discussion 
Summary  
This large population-based study provides the most comprehensive data yet on the long-term 
dynamics of thyroid function among elderly patients in primary care. The prevalence of subclinical 
hypothyroidism in this study population was 6·2%, similar to that reported in smaller studies.21 
Subclinical hyperthyroidism was less common, with just 1% of individuals being affected.  BETS 2 
confirms the incident findings of BETS 1, that subclinical thyroid dysfunction is a relatively 
common biochemical finding among elderly patients and therefore understanding the natural 
course of the disease is important for both clinicians and patients.16 
This study also demonstrates significant stability of thyroid function in this aging population over a 
long (mean 5 year) time interval with 96% of individuals who were euthyroid at baseline remaining 
so and less than 0·5% developing an overt hyper or hypothyroid status.  
 
Strengths and limitations  
This is the largest study to date following natural history of thyroid functioning in an unselected 
primary care cohort of older adults, with over 2900 individuals followed over a 5 year interval. One 
limitation of this study was that thyroid status on each occasion was based upon a single sample.  
There are several factors that can influence the reproducibility of TFTs, including seasonality 22 
and intercurrent illness 23, however, any subtle or transient change that may have occurred are 
unlikely to have influenced our findings in any significant fashion due to the large sample size and 
the likelihood of transient fluctuations impacting at both time points.  The predictive model needs 
to be interpreted with caution given low event rates. An automatic selection process to create a 
set of variables with the strongest association with the outcome was used, given this low event 
rate, however such a process is data driven and may create a biased selection.  However 
confidence is derived from the fact that all variables associated with development of 
hypothyroidism have strong biological plausibility. 
 
Comparison with existing literature  
Of those individuals classified as subclinically hypothyroid at baseline, only 2% progressed to 
overt hypothyroidism which is lower than has been previously reported. 24 Our study 
demonstrated 40% of such patients revert to euthryoid status which is in-line with the 15-65% 
estimate by Somwaru et al 25 and the majority of those with subclinical hypothyroidism at baseline 
retain a subclinical state despite the long screening interval. Similarly, just 4% of those who were 
subclinically hyperthyroid at baseline developed overt hyperthyroidism.  
To further support stability over time we demonstrate here that most individuals (61%) had almost 
no change in TSH (≤0·5 mIU/L), with equal numbers of individuals experiencing either increasing 
or decreasing TSH.  This contrasts with findings from previous work that suggests TSH  
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increases with age.26 In a similar manner, we also demonstrate that FT4 is remarkably stable over 
time in elderly subjects.  
In this study development of overt hypothyroid status was significantly more likely among 
individuals with a new diagnosis of either AF or renal disease, or recent commencement of 
amiodarone. This supports a previous finding that prevalence of subclinical hypothyroidism is 
higher among patients with chronic renal disease. 27 These factors along with previously high-
normal TSH or low-normal FT4 increase likelihood of hypothyroid dysfunction and may represent 
triggers for repeat testing although further work is needed to describe any benefit accrued from 
such a targeted approach. The large Odds Ratio with wide conference intervals observed for 
commencement of amiodarone during the follow-up period (92·1; 95% CI 5·64-1501·39) should 
however be interpreted with caution as it is likely an artefact of the very low prevalence of 
amiodarone use in the study cohort.  
Predictors of development of hyperthyroidism could not be determined from this study but 
considering the low incidence of hyperthyroidism there is nothing to support repeat testing of 
individuals with a normal test result within the previous 5 years to identify hyperthyroidism in the 
absence of substantive clinical signs and symptoms.  
 
Implications for practice  
This study confirms that older patients with subclinical thyroid dysfunction are only at small 
relative risk of progression to overt dysfunction, and absolute risk is very low.  TFTs are 
remarkably stable over extended periods and repeat routine testing or screening should be 
avoided in this population, particularly where a previous euthyroid result is reported in the clinical 
record. Considering this evidence, clinicians should minimise repeat TFT, unless clinically 
indicated, among elderly individuals who have a recent (within 5 years) euthyroid result in their 
clinical record. This is an important finding given that almost a third of older patients without overt 
thyroid dysfunction have at least one TFT performed annually (unpublished data). 
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Table 1: Reference ranges for thyroid function assays with their associated intra assay co-
efficient of variation. 
Test Reference Range Intra –assay co-efficient of 
variation (associated range)  
Thyroid Stimulating Hormone (TSH) 0·3-4·5 mlU/L 1·5% (0·5-33·0 mlU/L) 
Free Thyroxine (FT4) 10-22 pmol/L 2·0-2·5% (9·0-66.0 pmol/L) 
Free Triiodothyronine (FT3) 3·1-6·8 pmol/L 2·0-3·5 (4·0-21·0 pmol/L) 
 
 
Table 2: Thyroid status at baseline and follow-up 
 Follow-up (BETS 2) status (1 unclassified ) 
Baseline  
(BETS 1) 
status 
n=2936 Overt 
hypothyroid 
n= 9 
(0·3%) 
Subclinical 
hypothyroid 
n=181 
(6·2%) 
 
 
Euthyroid 
n= 2709 
 
(92·3%) 
Subclinical 
hyperthyroid 
n=29 
(0·99%) 
Overt 
hyperthyroid 
n= 8 
(0·3%) 
Subclinical 
hypothyroid  
(n=143) 
3 
(2.1%) 
83 
(58.0%) 
57 
(39.86%) 
0 0 
Euthyroid 
(n=2768) 
 
6 
(0.2%) 
 
 
98 
(3.5%) 
2644 
(95.5%) 
13 
(0.5%) 
7 
(0.3%) 
Subclinical 
hyperthyroid 
(n=25) 
0 0 
8 
(32.0%) 
16 
(64.0%) 
1 
(4.0%) 
Shaded cells indicate no status change over the screening interval 
 
Table 3: Logistic regression – factors associated with development of hypothyroidism and 
associated likelihood 
Variable Co 
efficient 
P-value OR Lower 95 
% CI for 
OR 
Upper 95 
% CI for 
OR 
Baseline TSH 0·38 0·001 1·46 1·17 1·81 
Baseline FT4 -0·86 <0·001 0·42 0·27 0·66 
New* amiodarone prescription 4·61 0·001 92·1 5·64 1501·39 
New* AF diagnosis 2·00 0·012 7·41 1·56 35·14 
New* renal disease diagnosis 1·57 0·044 4·81 1·04 22·22 
31 variables were available for construction of logistic regression models, comprising 22 disease categories, 
amiodarone use, alcohol use, smoking status, family history of thyroid dysfunction, age, gender, IMD score and 
baseline TSH and FT4.  Seven disease groups and family history were removed to maximise the dataset 
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available for analysis were data were missing for 1% or more of the population. The forward stepwise method 
was used with a significance level of 5% for variable inclusion and 10% for variable removal. Eight variables 
were entered to the final model although existing (at baseline) diagnoses of AF, renal disease or amiodarone 
use did not make a significant contribution to the final model. 
* ‘New’ relates to prescription or diagnosis occurring for the first time after the initial baseline 
screening episode 
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